T1	intervention 69 98	trastuzumab emtansine (T-DM1)
T2	control 106 132	capecitabine and lapatinib
T3	outcome-Measure 615 640	time to symptom worsening
T4	iv-bin-abs 1143 1146	450
T5	intervention-participants 1150 1153	495
T7	cv-bin-abs 1220 1223	445
T8	control-participants 1227 1230	496
T9	outcome 1280 1305	Time to symptom worsening
T10	iv-cont-median 1379 1389	7.1 months
T11	cv-cont-median 1397 1407	4.6 months
T14	outcome 1503 1549	clinically significant improvement in symptoms
T15	iv-bin-percent 1475 1480	55.3%
T16	cv-bin-percent 1571 1576	49.4%
T6	outcome 1199 1212	TOI-PFB score
